Tuesday, 9 June 2026
TGA guidance on compounding medicines, Chronic kidney disease reviews, Myostatin inhibitor for muscle loss
- 01
New TGA Guidance on Compounded Medicines Released
The federal government has issued new guidance clarifying the requirements for compounding medicines, as announced by the TGA. This guidance outlines how pharmacists and medical practitioners can lawfully compound medicines under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. It details the conditions under which exemptions from manufacturing licensing requirements may apply and the restrictions on prescription medicines requiring compounding. The TGA emphasised the importance of compliance, noting serious penalties for breaches of the Act, including substantial fines and potential imprisonment.
- 02
New Reviews Transform Understanding of Chronic Kidney Disease
Three new reviews published in The Lancet detail significant advances in the diagnosis and treatment of chronic kidney disease (CKD). Researchers highlight the importance of early detection, combination drug therapies, and recognition of sex-specific differences in improving patient outcomes. The reviews challenge the traditional view of CKD as a progressive condition, advocating for its recognition as a treatable multisystem disorder. They also emphasise the need for improved screening practices, particularly among at-risk populations, to enhance early diagnosis and management.
- 03
Myostatin Inhibitor Reduces Muscle Loss During Weight Loss
A phase 2 trial has demonstrated that a myostatin inhibitor can reduce lean mass loss in patients undergoing treatment with tirzepatide. This finding is significant for managing obesity and metabolic health. The results may influence future approaches in primary care for weight management. Further details on the trial's methodology and outcomes were not provided.
- 04
PBS Changes Improve Access to Migraine Treatments
Recent changes to the Pharmaceutical Benefits Scheme (PBS) enhance access to treatments for migraine sufferers in Australia. These adjustments aim to provide relief for patients by making necessary medications more readily available. The changes are significant for individuals affected by migraines, potentially improving their quality of life. This development is noteworthy as it reflects ongoing efforts to address medication access in the Australian healthcare system.
- 05
BD Recalls ChloraPrep™ and FREPP™ Applicators Due to Contamination
BD is recalling specific lots of ChloraPrep™ Clear 1 mL and FREPP™ Clear 1.5 mL applicators due to fungal contamination. The affected lot numbers are 4032183 for ChloraPrep™ and 4073005 for FREPP™. This recall is significant as it affects products used in clinical settings, raising safety concerns. The recall is voluntary and has been issued to the consumer level.
via FDA MedWatch
- 06
Professor Richard Scolyer, pioneer in brain cancer research, dies at 59
Professor Richard Scolyer, a prominent pathologist and joint Australian of the Year for 2024, has died at 59 after a battle with advanced glioblastoma. He volunteered for a groundbreaking experimental treatment that combined immunotherapy techniques, leading to significant insights for future brain cancer therapies. His treatment success resulted in the establishment of a clinical trial aimed at adapting this approach for broader use. Scolyer's legacy will influence the treatment of glioblastoma and potentially other cancers, impacting countless patients in the years to come.
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.